SERINA THERAPEUTICS INC.
SERNYSE AMERICAN🏆 #4568 by market capEarnings Nov 18US Equity
$1.63▼ $0.08 (−4.68%)
Pre-market · at closeTrack SER
Get earnings, price moves & breaking news on Telegram
24h▼ 4.7%
7d▼ 8.4%
14d▼ 16.0%
30d▼ 20.1%
ytd▼ 12.4%
1y▼ 67.6%
🏦Market Cap
$24M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.61 – $1.63
- 52-Week Range
- $1.22 – $5.06
- Volume (shares)
- 206
- Avg Volume (shares)
- —
- Shares Outstanding
- 15.0M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.29
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −5.2%
SERINA THERAPEUTICS INC.
SERFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-246.4%▼ −353.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$24M▲ +40.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$18M▲ +4.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.2M▼ −5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$86K▼ −$3M YoY
StockOtter · stockotter.spaceAbout SERINA THERAPEUTICS INC.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
6 analysts
Strong Buy2
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.